Daiichi Sankyo’s Vanflyta (quizartinib) has been recommended by the National Institute for Health and Care Excellence (NICE) ...

Fasenra (benralizumab) has been approved by the US Food and Drug Administration (FDA) to treat adults with eosinophilic ...

Merck & Co – known as MSD outside the US and Canada – and Daiichi Sankyo have announced that a late-stage trial of patritumab ...

Post-treatment follow-up of patients is not new. Traditional follow-up studies may last two to five years, while long-term ...

Ever wondered where 'KOLs' came from and why they matter? Dr Alex Loveday answers those questions in this latest edition of ...

Merck & Co – known as MSD outside the US and Canada – has received approval from the US Food and Drug Administration (FDA) ...

GSK has shared positive headline results for its mRNA seasonal influenza vaccine and outlined that it will now progress the ...

Merck & Co – known as MSD outside the US and Canada – has shared positive overall survival (OS) results from a late-stage ...

Eli Lilly has announced that the US Food and Drug Administration (FDA) has approved its targeted IL-13 inhibitor Ebglyss (lebrikizumab-lbkz) to treat moderate-to-severe atopic dermatitis (AD). The ...

Roche’s injectable PD-L1 inhibitor Tecentriq Hybreza (atezolizumab and hyaluronidase-tqjs) has been approved by the US Food ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) as an add-on maintenance treatment for chronic obstructive pulmonary ...

Regeneron Pharmaceuticals has shared positive five-years results from a late-stage study of Libtayo (cemiplimab) in advanced lung cancer. The phase 3 EMPOWER-Lung 1 trial compared the monoclonal ...